Organon Investor Presentation — December 2021 - Organon

Document content

Q4 and Full Year 2021 EarningsOrganonDisclaimer statement

This text should be viewed in conjunction with Organon’s Full Year/ Q42021 earnings call

2Safe Harbor for Forward -Looking Statements

Except for historical information herein, this news release includes “forward -looking statements” within the meaning of the safe harbor

provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about mana gement’s

expectations about Organon’s future financial performance and prospects. Forward -looking statements may be identified by words s uch as

“expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These sta tements are based upon

the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If u nderlying

assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth inthe forward -looking

statements. Risks and uncertainties include, but are not limited to, an inability to execute on our business development stra tegy or realize the

benefits of our planned acquisitions; general industry conditions and competition; general economic factors, including intere st rate and currency

exchange rate fluctuations; the impact of the ongoing COVID -19 pandemic and emergence of variant strains; the impact of pharmace utical

industry regulation and health care legislation in the United States and internationally; global trends toward health care co st containment;

technological advances; new products and patents attained by competitors; challenges inherent in new product development, inc luding

obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to

accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international eco nomies and sovereign

risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of the company’s

patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or re gulatory actions. The

company undertakes no obligation to publicly update any forward -looking statement, whether as a result of new information, futur e events or

otherwise. Additional factors that could cause results to differ materially from those described in the forward -looking statemen ts can be found in

the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10 and subsequent